HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

Inclusion Criteria: 1. Age 18 \~ 70 years old (including 70 years old), male and female; 2. Patients with hepatohcellular carcinoma diagnosed clinically or confirmed by histology / cytology ; 3. Patients with unresectable or metastatic hepatocellular carcinoma; 4. No systematic treatment. Patients recieved previously systematic treatment and progressed can also be included in the group; 5. Patients who underwent hepatectomy in the past should be R0 resection, and the tumor recurrence should be more than 6 months after operation; 6. At least one assessable lesion (mRECIST criteria); 7. Expected survival time ≥ 3 months; 8. ECOG 0 \~ 1; 9. Child Pugh ≤ 7; 10. Be able to cooperate to observe adverse events; 11. Major organs are functioning normally: * Hemoglobin ≥ 90 g / L; * ANC ≥ 1.5 × 109/L； * Platelet count ≥ 75 × 109/L； * Albumin ≥ 28 g / L; * Total bilirubin ≤ 2 × ULN; * AST, ALT ≤ 5 × ULN； * ALP ≤ 5 × ULN； * Creatinine ≤ 1.5 × ULN； * INR or PT ≤ 1.5 × ULN； J) APTT ≤ 1.5 × ULN。 Exclusion Criteria: 1. History of symptomatic congestive heart failure, unstable angina pectoris, 2. Uncontrolled cardia arrhythmia 3. History of hepatic encephalopathy 4. Uncontrolled arterial hypertension 5. Co-infection with HBV and HDV